붕소 (남성 호르몬)
Boron (Testosterone)
📚 관련 논문 (16편)
1. Biol Trace Elem Res. 1998 Winter;66(1-3):227-35. doi: 10.1007/BF02783140. The nutritional and metabolic effects of boron in humans and animals. Samman S(1), Naghii MR, Lyons Wall PM, Verus AP. Author information: (1)Department of Biochemistry, University of Sydney, NSW, Australia. We have und
1. Food Sci Nutr. 2025 Aug 11;13(8):e70777. doi: 10.1002/fsn3.70777. eCollection 2025 Aug. The Effect of Boron Supplementation on Kidney Stones in Patients With Nephrolithiasis: A Double-Blind Randomized Controlled Trial. Vousoughi G(1), Soleimanzadeh H(2), Radkhah N(1), Asghari Jafarabadi M(3)(4)(5), Bahri F(1), Ostadrahimi A(2), Ebrahimzadeh Attari V(6). Author information: (1)Student Research Committee, Tabriz University of Medical Sciences Tabriz Iran. (2)Nutrition Research Center Tabriz University of Medical Sciences Tabriz Iran. (3)Cabrini Research Cabrini Health Malvern Victoria Australia. (4)School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia. (5)Department of Psychiatry School of Clinical Sciences, Monash University Clayton Victoria Australia. (6)Department of Biochemistry and Nutrition School of Nutrition and Food Sciences, Tabriz University of Medical Sciences Tabriz Iran. Kidney stones (nephrolithiasis) are a common and costly medical condition frequently linked with metabolic disorders. These disorders elevate the risk of serious complications and often necessitate invasive, expensive treatments, highlighting the need for alternative therapies. This study aimed to evaluate the effects of boron supplementation-in the form of boric acid and boron citrate-on kidney stone size and number in patients with nephrolithiasis. In this double-blind, randomized, placebo-controlled clinical trial, 60 eligible patients aged 20-65 years with nephrolithiasis were enrolled. Participants were randomly assigned to receive daily oral supplements for 8 weeks: boric acid (10 mg), boron citrate (10 mg), or placebo. The primary outcomes were kidney stone size and number; secondary outcomes included paraclinical parameters. Boron supplementation with either boric acid or boron citrate did not significantly reduce the number of kidney stones in fully adjusted models compared to the control group. The incidence rate ratios (IRR) were 1.09 (95% CI: 0.65-1.85; p-value = 0.740) for boric acid and 1.30 (95% CI: 0.79-2.13; p-value = 0.296) for boron citrate. Quade analysis also revealed no significant differences in kidney stone size among the groups. Regarding laboratory parameters, only urine phosphorus levels were significantly elevated in the boric acid group compared to placebo. No other clinically relevant effects were observed. Despite previous preliminary evidence, this study found no beneficial evidence for boron supplementation in patients with nephrolithiasis. Trial Registration: IRCT20210914052469N1 (www.irct.behdasht.gov.ir). © 2025 The Author(s). Food Science & Nutrition published by Wiley Periodicals LLC. DOI: 10.1002/fsn3.70777 PMCID: PMC12336847 PMID: 40792045 Conflict of interest statement: The authors declare no conflicts of interest.
2. Br J Nutr. 2024 Aug 14;132(3):315-329. doi: 10.1017/S0007114524001132. Epub 2024 May 31. Evaluating mineral biomarkers as mediators and moderators of behavioural improvements in a randomised controlled trial of multinutrients for children with attention-deficit/hyperactivity disorder. Robinette LM(#)(1), Johnstone JM(#)(2)(3), Srikanth P(4), Bruton AM(2), Ralle M(5), Ast HK(2), Bradley RD(3)(6), Leung B(7), Arnold LE(8), Hatsu IE(1)(9). Author information: (1)Department of Human Sciences, The Ohio State University, Columbus, OH, USA. (2)Center for Mental Health Innovation, Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA. (3)National University of Natural Medicine, Helfgott Research Institute, Portland, OR, USA. (4)Oregon Health & Science University, Portland, OR, USA. (5)Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA. (6)Herbert Wertheim School of Public Health, University of California San Diego, San Diego, CA, USA. (7)Faculty of Health Sciences, University of Lethbridge, Lethbridge, AB, Canada. (8)Department of Psychiatry & Behavioral Health, The Ohio State University, Columbus, OH, USA. (9)OSU Extension, The Ohio State University, Columbus, OH, USA. (#)Contributed equally Essential minerals are cofactors for synthesis of neurotransmitters supporting cognition and mood. An 8-week fully-blind randomised controlled trial of multinutrients for attention-deficit/hyperactivity disorder (ADHD) demonstrated three times as many children (age 6-12) had significantly improved behaviour ('treatment responders') on multinutrients (54 %) compared with placebo (18 %). The aim of this secondary study was to evaluate changes in fasted plasma and urinary mineral concentrations following the intervention and their role as mediators and moderators of treatment response. Fourteen essential or trace minerals were measured in plasma and/or urine at baseline and week eight from eighty-six participants (forty-nine multinutrients, thirty-seven placebos). Two-sample t tests/Mann-Whitney U tests compared 8-week change between treatment and placebo groups, which were also evaluated as potential mediators. Baseline levels were evaluated as potential moderators, using logistic regression models with clinical treatment response as the outcome. After 8 weeks, plasma boron, Cr (in females only), Li, Mo, Se and vanadium and urinary iodine, Li and Se increased more with multinutrients than placebo, while plasma phosphorus decreased. These changes did not mediate treatment response. However, baseline urinary Li trended towards moderation: participants with lower baseline urinary Li were more likely to respond to multinutrients (P = 0·058). Additionally, participants with higher baseline Fe were more likely to be treatment responders regardless of the treatment group (P = 0·036.) These results show that multinutrient treatment response among children with ADHD is independent of their baseline plasma mineral levels, while baseline urinary Li levels show potential as a non-invasive biomarker of treatment response requiring further study. © The Author(s), 2024. Published by Cambridge University Press on behalf of The Nutrition Society DOI: 10.1017/S0007114524001132 PMCID: PMC11473203 PMID: 38818718 [Indexed for MEDLINE] Conflict of interest statement: The other authors declare that the research was conducted without any conflict of interest.
3. BMJ Open. 2023 Dec 10;13(12):e075941. doi: 10.1136/bmjopen-2023-075941. Effects of boron citrate supplementation on cardiometabolic factors, inflammatory biomarkers and anthropometric measures in obese patients: study protocol for a randomised, double-blind clinical trial. Naemi M(1), Naghshi S(2), Rostami S(2), Safaei E(3), Tutunchi H(4), Ostadrahimi A(5). Author information: (1)Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. (2)Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. (3)Food Science and Human Nutrition Department, University of Florida, Gainesville, Florida, USA. (4)Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran helda.nutrition@gmail.com ostadrahimi@tbzmed.ac.ir. (5)Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition& Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran helda.nutrition@gmail.com ostadrahimi@tbzmed.ac.ir. INTRODUCTION: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. The efficacy and safety of boron citrate (BC), a novel therapeutic approach, in patients with obesity are not known. The current trial will take place to determine the effects of BC supplementation on cardiometabolic factors, inflammatory biomarkers, anthropometric measures and body composition in obese patients. METHODS AND ANALYSIS: This double-blind, placebo-controlled, randomised clinical trial will involve 60 eligible obese participants aged 18-60 years. Participants will randomly be allocated to receive either BC capsules (containing 10 mg of boron) in the intervention group or placebo capsules (containing 10 mg of maltodextrin) in the placebo group for 12 weeks. Moreover, physical activity and dietary recommendations will be provided for both groups. To assess the dietary intakes of participants, a 3-day food record (2 days of the week and 1 day of the weekend) will be filled. Cardiometabolic factors, inflammatory biomarkers including tumour necrosis factor α, C reactive protein, interleukin-6 and interleukin-10 levels, anthropometric measures and body composition will be assessed at the baseline and end of the intervention. The findings of this study will provide evidence for the effectiveness of BC in the management of obesity. ETHICS AND DISSEMINATION: There are so far no reported adverse effects associated with the use of boron. This trial was approved by the Ethics Committee of Tabriz University of Medical Sciences (approval number: IR.TBZMED.REC.1401.350). Positive as well as negative findings will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: IRCT20220806055624N1. © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. DOI: 10.1136/bmjopen-2023-075941 PMCID: PMC10729199 PMID: 38072490 [Indexed for MEDLINE] Conflict of interest statement: Competing interests: None declared.
4. Biol Trace Elem Res. 2023 Nov;201(11):5126-5133. doi: 10.1007/s12011-023-03597-0. Epub 2023 Feb 21. A Comparison of Boron Supplement and Tamsulosin as Medical Expulsive Therapy for Urinary Stones After Extracorporeal Shock Wave Lithotripsy: a Randomized Controlled Clinical Trial. Jalali S(1), Borumandnia N(2), Basiri A(2), Nagiee M(3), Amiri FB(4), Tavasoli S(2), Kheirolahkhani Y(5), Taheri M(6). Author information: (1)University of British Columbia, Vancouver, British Columbia, Canada. (2)Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, No. 103, Shahid Jafari (9Th Boostan) St., Pasdaran Ave, IR 1666663111, Tehran, Iran. (3)Baqiyatallah University of Medical Sciences, Tehran, Islamic Republic of Iran. (4)Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran. (5)Shahid Beheshti University of Medical Sciences, Tehran, IR, Iran. (6)Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, No. 103, Shahid Jafari (9Th Boostan) St., Pasdaran Ave, IR 1666663111, Tehran, Iran. taherim@sbmu.ac.ir. Treatment with alpha-blockers has been used in many studies to facilitate stone clearance after extra-corporeal shock wave lithotripsy (ESWL), based on mediating ureteral wall relaxation. Ureteral wall edema is another barrier against the stone passage. We aimed to compare the effectiveness of boron supplement (due to its anti-inflammatory effect) and tamsulosin in the passage of stone fragments after ESWL. Eligible patients after ESWL were randomly assigned to two groups and were treated with boron supplement (10 mg/BD) or tamsulosin (0.4 mg per night) for 2 weeks. The primary outcome was the stone expulsion rate according to the remained fragmented stone burden. The secondary outcomes were the time of stone clearance, pain intensity, drug side effects, and the need for auxiliary procedures. In this randomized control trial, 200 eligible patients were treated with boron supplement or tamsulosin. Finally, 89 and 81 patients in the two groups completed the study, respectively. The expulsion rate was 46.6% in the boron and 38.7% in the tamsulosin group, which there was no statistically significant difference between the two groups (p = 0.003), as well as the time of stone clearance (7.47 ± 22.4 vs 6.52 ± 18.45, days, p = 0.648, respectively), after 2-week follow-up. Moreover, pain intensity was the same in both groups. No Significant side effects were reported in the two groups. Boron supplement could be effective as adjuvant medical expulsive therapy after ESWL with no significant side effects in short-term follow-up. Iranian Clinical Trial Registration number and date of registration: IRCT20191026045244N3, 07/29/2020. © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. DOI: 10.1007/s12011-023-03597-0 PMID: 36808295 [Indexed for MEDLINE]
5. J Trace Elem Med Biol. 2022 May;71:126945. doi: 10.1016/j.jtemb.2022.126945. Epub 2022 Feb 12. Possible therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19: A pilot randomized, double-blind, clinical trial. Akbari N(1), Ostadrahimi A(2), Tutunchi H(1), Pourmoradian S(2), Farrin N(2), Najafipour F(1), Soleimanzadeh H(3), Kafil B(4), Mobasseri M(5). Author information: (1)Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. (2)Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. (3)Department of Applied Chemistry, Faculty of Chemistry, University of Tabriz, Iran. (4)Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. (5)Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: mobasserimajid@yahoo.com. BACKGROUND: The present study aimed to assess the therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19. METHODS: Forty adult patients with a diagnosis of COVID-19 were recruited in the present study. Patients were randomized in a 1:1:1:1 allocation ratio to 1of 4 treatment groups: (A) 5 mg of boron citrate twice a day, (B) 200 mg of oleoylethanolamide twice a day, (C) both therapies, or (D) routine treatments without any study medications. At pre-and post-intervention phase, some clinical and biochemical parameters were assessed. RESULTS: Supplementation with boron citrate alone or in combination with oleoylethanolamide significantly improved O2 saturation and respiratory rate (p < 0.01). At the end of the study, significant increases in white blood cell and lymphocyte count were observed in the boron citrate and combined groups (p < 0.001). Boron citrate supplementation led to a significant decrease in serum lactate dehydrogenase (p = 0.026) and erythrocyte sedimentation rate (p = 0.014), compared with other groups. Furthermore, boron citrate in combination with oleoylethanolamide resulted in a significant reduction in the high-sensitivity C-reactive protein and interleukin-1β concentrations (p = 0.031 and p = 0.027, respectively). No significant differences were found among four groups post-intervention, in terms of hemoglobin concentrations, platelet count, and serum interleukin-6 levels. At the end of the study, common symptoms of COVID-19 including cough, fatigue, shortness of breath, and myalgia significantly improved in the supplemented groups, compared to the placebo (p < 0.05). CONCLUSION: Supplementation with boron citrate alone or in combination with oleoylethanolamide could improve some clinical and biochemical parameters in COVID-19 patients. Copyright © 2022 Elsevier GmbH. All rights reserved. DOI: 10.1016/j.jtemb.2022.126945 PMCID: PMC8837486 PMID: 35183882 [Indexed for MEDLINE] Conflict of interest statement: All authors declare that there is no conflict of interest.
6. Trials. 2020 Oct 27;21(1):890. doi: 10.1186/s13063-020-04820-2. Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Tutunchi H(1), Mobasseri M(2), Pourmoradian S(3), Soleimanzadeh H(4), Kafil B(3), Akbari N(3), Monshikarimi A(3), Ostadrahimi A(5). Author information: (1)Department of Clinical Nutrition, Nutrition Research Center, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz, 5166614711, Iran. (2)Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. (3)Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. (4)Department of Applied Chemistry, Faculty of Chemistry, University of Tabriz, Tabriz, Iran. (5)Department of Clinical Nutrition, Nutrition Research Center, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz, 5166614711, Iran. ostadrahimi@tbzmed.ac.ir. OBJECTIVES: In this study, we investigate the effect of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19. TRIAL DESIGN: The current study is a single-center, randomized, double-blind, placebo-controlled clinical trial with parallel groups. PARTICIPANTS: The inclusion criteria include male and female patients≥18 years of age, with a confirmed diagnosis of SARS-CoV-2 infection via polymerase chain reaction (PCR) and/or antibody test and with written informed consent to participate in this trial. The exclusion criteria include regular use of any other supplement, severe and critical COVID-19 pneumonia, pregnancy and breastfeeding. This study is being conducted at Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. INTERVENTION AND COMPARATOR: Patients are randomly assigned to four groups. The first group (A) will take one capsule containing 5 mg of boron compounds twice a day for two weeks. The second group (B) will take one capsule containing 200 mg oleoylethanolamide twice a day for two weeks. The third group (C) will take one capsule containing 5 mg boron compounds with 200 mg oleoylethanolamide twice a day for two weeks, and the fourth group (D) does not receive any additional treatment other than routine treatments. Boron-containing compounds and oleoylethanolamide capsules will be synthesized at Nutrition Research Center of Tabriz University of Medical Sciences. MAIN OUTCOMES: The primary end point of this study is to investigate the recovery rate of clinical symptoms, including fever, dry cough, and fatigue, as well as preclinical features, including complete blood count (CBC), the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) profiles within two weeks of randomization. RANDOMISATION: Patients are randomized into four equal groups in a parallel design (allocation ratio 1:1). A randomized block procedure is used to divide subjects into one of four treatment blocks (A, B, C, and D) by a computer-generated allocation schedule. BLINDING (MASKING): The participants and investigators (enrolling, assessing, and analyzing) are blinded to the intervention assignments until the end of the study and data analysis. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The calculated total sample size is 40 patients, with 10 patients in each group. TRIAL STATUS: The protocol is Version 1.0, May 17, 2020. Recruitment began May 19, 2020, and is anticipated to be completed by October 19, 2020. TRIAL REGISTRATION: This clinical trial has been registered by the title of "Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in Patients with COVID-19: A double-blind randomized placebo-controlled clinical trial" in the Iranian Registry of Clinical Trials (IRCT). The registration number is " IRCT20090609002017N35 ", https://www.irct.ir/trial/48058 . The registration date is 17 May 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. DOI: 10.1186/s13063-020-04820-2 PMCID: PMC7588946 PMID: 33109244 [Indexed for MEDLINE] Conflict of interest statement: The authors declare that they have no competing interests.
7. Biol Trace Elem Res. 2018 May;183(1):16-21. doi: 10.1007/s12011-017-1105-0. Epub 2017 Aug 15. Association of Elements with Schizophrenia and Intervention of Selenium Supplements. Li Z(1), Liu Y(1), Li X(1), Ju W(1), Wu G(1), Yang X(1), Fu X(1), Gao X(2). Author information: (1)Shandong University, Number 44 in Wenhua Road, Lixia Distrct, Jinan, China. (2)Shandong University, Number 44 in Wenhua Road, Lixia Distrct, Jinan, China. chem@sdu.edu.cn. The purpose of this study is to explore more trace elements (zinc, potassium, copper, iron, boron, manganese, selenium, chromium and cadmium elements) in addition to calcium, magnesium, lead and arsenic in the sera of patients with schizophrenia and the general population in China and to determine the effect of selenium on schizophrenia patients. Participants were collected from the Pingyin County Mental Health Hospital and Pingyin County. A t test was used to analyse the differences between schizophrenia patients and healthy subjects, and element content differences in gender. Logistic multivariate regression analysis was applied to analyse the influence of elements to schizophrenia. Repeated measures analysis of variance was used to analyse differences in the elements after 1 and 3 months. Mn, Se, Cd, Pb, Ca, Cu and Fe were lower than those in the normal group, and B, Cr, As, K and Mg were higher than those in the control group. The odd ratios (ORs) of serum As and serum K were 2.624 and 1.035, respectively. The ORs of sera Cr, Mn, Se, Ca and Cu were all below one. After intervention of 'selenium weikang' about 1 and 3 months, the serum As was decreased and the serum selenium and copper were increased. Cr, Mn, Se, Ca and Cu might have beneficial, statistically significant effects on schizophrenia. Elements As and K might be harmful to schizophrenia with statistical significance. After selenium supplementation, the schizophrenia patients improved in some factors, like the appetite and memory, and the As element decreased. DOI: 10.1007/s12011-017-1105-0 PMID: 28812245 [Indexed for MEDLINE]
8. J Intercult Ethnopharmacol. 2016 Dec 8;6(1):58-64. doi: 10.5455/jice.20161204021549. eCollection 2017 Jan-Mar. The adjuvant use of calcium fructoborate and borax with etanercept in patients with rheumatoid arthritis: Pilot study. Hussain SA(1), Abood SJ(2), Gorial FI(3). Author information: (1)Faculty of Pharmacy, Alrafidain University College, Baghdad, Iraq. (2)Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq. (3)Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq. OBJECTIVE: This study was designed to evaluate the effects calcium fructoborate (CFB) and sodium tetraborate (NTB) as supplements in Iraqi patients with active rheumatoid arthritis (RA) maintained on etanercept. MATERIALS AND METHODS: A double-blind randomized placebo-controlled clinical trial with 60 days treatment period was carried out at Baghdad Teaching Hospital, Medical city, Baghdad, Iraq. Eighty RA patients were randomized into three groups to receive either 220 mg/day CFB, 55 mg/day NTB in capsule dosage form (equivalent to 6 mg elemental Boron), or placebo formula once daily. Only 72 patients completed the study. All patients were clinically evaluated utilizing DAS28-erythrocyte sedimentation rate (ESR), simple disease activity index-C-reactive protein (CRP), and clinical disease activity index scores at baseline, and at the end of the study. Venous blood was obtained at baseline and after 60 days, and utilized for the measurement of ESR, hemoglobin, in addition to evaluation of high-sensitivity CRP (hsCRP), tumor necrosis factor-α (TNF-α), interleukin-1α (IL-1α) and IL-6. RESULTS: After 60 days, both types of boron significantly improve the clinical scores, in association with significant decrease in the serum levels of ESR, hsCRP, IL-1α, IL-6, and TNF-α with remarkable superiority for calcium fructoborate (CFB) over sodium tetraborate (NTB), compared to baseline and placebo-treated group. CONCLUSION: The use of boron, as adjuvant with etanercept, has potentiated therapeutic outcomes in RA patients, and may be a new strategy to improve treatment, and avoid the problems associated with biologics utilized in RA treatment. DOI: 10.5455/jice.20161204021549 PMCID: PMC5289089 PMID: 28163961 Conflict of interest statement: Conflicts of Interest: None declared.
9. Animal. 2015 Aug;9(8):1298-303. doi: 10.1017/S1751731115000579. The effect of dietary cadmium supplementation on performance, egg quality, tibia biomechanical properties and eggshell and bone mineralisation in laying quails. Olgun O(1). Author information: (1)Department of Animal Science, Faculty of Agriculture,Selcuk University,42075 Konya,Turkey. The aim of this study was to investigate the effects of different levels of cadmium supplementation (0, 5, 10, 20, 40 and 80 mg/kg) in the diet on performance, egg quality, tibia biomechanical properties and eggshell and bone mineral contents in laying quails. In this 10-week trial, a total of 96 laying quails, aged 21 weeks, were randomly distributed among six experimental groups. Each experimental group contained four replicates of four birds each. The performance parameters were adversely affected quadratically when cadmium was added to the diets in the concentrations of 20 mg/kg and above (P<0.01). The specific gravity and eggshell weight were maximal with the addition of 20 mg/kg cadmium to the diet. The biomechanical properties of the tibia were negatively affected by cadmium supplementation in quails (P<0.05). The eggshell boron content decreased linearly (P<0.001) with cadmium supplementation to the diet. The cadmium content in bone increased when cadmium was added to the diets (P<0.001). The bone boron concentration decreased as dietary cadmium supplementation was increased (P<0.001). DOI: 10.1017/S1751731115000579 PMID: 26190251 [Indexed for MEDLINE]
10. Complement Ther Clin Pract. 2015 May;21(2):79-83. doi: 10.1016/j.ctcp.2015.03.005. Epub 2015 Apr 4. Effects of boron supplementation on the severity and duration of pain in primary dysmenorrhea. Nikkhah S(1), Dolatian M(2), Naghii MR(3), Zaeri F(4), Taheri SM(5). Author information: (1)Department of Midwifery, Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran. (2)Department of Midwifery, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: mhdolatian@gmail.com. (3)Department of Nutrition, Health School, Baqiyatallah (a.s.) University of Medical Sciences, Tehran, Iran. (4)Department of Biostatistics, Faculty of Paramedicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. (5)Department of Surgery, Faculty of Medicine, Baqiyatallah (a.s.) University of Medical Sciences, Tehran, Iran. BACKGROUND: Primary dysmenorrhea refers to painful menstrual cramps without pelvic pathology. The condition is highly prevalent among women and exerts negative effects on their quality of life. Considering the evidence for anti-inflammatory properties of Boron, the present study aimed to determine the effects of Boron supplementation on the severity and duration of menstrual pain in female university students. METHODS: This triple-blind randomized clinical trial study recruited 113 university students. The participants were matched for the severity and duration of dysmenorrhea and randomly allocated into the case and control groups (n = 58 and 55, respectively). The case group consumed 10 mg/day Boron from two days before the menstrual flow until its third day. The control group received placebo capsules (similar to those distributed among the cases). All subjects were asked to take the capsules for two consecutive menstrual cycles. Pain severity (measured on a visual analog scale) and duration (in hours) were measured at baseline and during the two cycles. RESULTS: The two groups had no significant differences in the severity and duration of pain at baseline. After the intervention, however, the severity and duration of pain were significantly lower in the case group than in the control group (P < 0.05). CONCLUSION: Based on our findings, Boron supplementation can reduce the severity and duration of menstrual pain through exerting anti-inflammatory effects. In order to clarify the effects of Boron on dysmenorrhea, future studies are required to measure the levels of hormones and inflammatory biomarkers. Copyright © 2015 Elsevier Ltd. All rights reserved. DOI: 10.1016/j.ctcp.2015.03.005 PMID: 25906949 [Indexed for MEDLINE]
11. J Clin Oncol. 2013 Sep 10;31(26):3279-87. doi: 10.1200/JCO.2012.48.4626. Epub 2013 Jul 29. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. Sonneveld P(1), Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P. Author information: (1)Pieter Sonneveld, Erasmus Medical Center, Rotterdam; Henk M. Lokhorst, Utrecht Medical Center, Utrecht, the Netherlands; Hartmut Goldschmidt, University Hospital of Heidelberg, Heidelberg, Germany; Laura Rosiñol, Joan Bladé, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid, Spain; Michele Cavo, Paola Tacchetti, Elena Zamagni, Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Bologna, Italy; Michel Attal, Hopital Purpan, Toulouse; Philippe Moreau, University Hospital, Nantes, France; Avinash Desai, Janssen Global Services; Kevin Liu, Janssen Research and Development, Raritan, NJ; Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA; Andrew Cakana, Janssen Research and Development, High Wycombe, United Kingdom; Helgi van de Velde, Janssen Research and Development, Beerse, Belgium. PURPOSE: To characterize efficacy and safety of bortezomib-based versus nonbortezomib-based induction regimens through an integrated analysis of data from phase III studies in transplantation-eligible patients with previously untreated myeloma. PATIENTS AND METHODS: Patient-level data from the IFM 2005-01 (bortezomib-dexamethasone v vincristine-doxorubicin-dexamethasone [VAD] induction), HOVON-65/GMMG-HD4 (bortezomib-doxorubicin-dexamethasone v VAD), and PETHEMA GEM05MENOS65 (bortezomib-thalidomide-dexamethasone v thalidomide-dexamethasone) studies were pooled in an integrated analysis of efficacy and safety. Study-level data from the GIMEMA MM-BO2005 study (bortezomib-thalidomide-dexamethasone v thalidomide-dexamethasone) supplemented the integrated patient-level analysis. Key efficacy end points were post-transplantation complete plus near-complete response (CR+nCR) rate and progression-free survival (PFS). RESULTS: Patient-level data for 1,572 patients (bortezomib-based induction, n = 787; nonbortezomib-based induction, n = 785) were included. Post-transplantation CR+nCR rate was significantly higher following bortezomib-based versus nonbortezomib-based induction (38% v 24%; odds ratio, 2.05; P < .001); the benefit remained similar (pooled odds ratio, 1.96) when GIMEMA MM-BO2005 data were included. Median PFS was 35.9 months versus 28.6 months with bortezomib-based versus nonbortezomib-based induction, respectively (hazard ratio, 0.75; P < .001); 3-year overall survival (OS) rates were 79.7% and 74.7%, respectively (hazard ratio for OS, 0.81; P = .0402). Median duration of induction treatment was 11 weeks in both treatment groups. Rates of peripheral neuropathy during induction were 34% versus 17% (grade ≥ 3, 6% v 1%). Overall, 3% and 4% of patients died during bortezomib-based and nonbortezomib-based induction, respectively. CONCLUSION: Bortezomib-based induction results in significant improvements in response and PFS/OS compared with nonbortezomib-based induction and is generally well tolerated, with a higher rate of peripheral neuropathy but no apparent increase in risk of death during induction. DOI: 10.1200/JCO.2012.48.4626 PMID: 23897961 [Indexed for MEDLINE]
12. Biomed Res Int. 2013;2013:273498. doi: 10.1155/2013/273498. Epub 2012 Dec 31. The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. Bitto A(1), Burnett BP, Polito F, Russo S, D'Anna R, Pillai L, Squadrito F, Altavilla D, Levy RM. Author information: (1)Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, 98125 Messina, Italy. abitto@unime.it An FDA-regulated, prescription medical food (Fosteum; 27 mg natural genistein, 200 IU cholecalciferol, 20 mg citrated zinc bisglycinate (4 mg elemental zinc) per capsule) and an over-the-counter (OTC) supplement (Citracal Plus Bone Density Builder; 27 mg synthetic genistein, 600 mg elemental calcium (calcium citrate), 400 IU vitamin D3, 50 mg magnesium, 7.5 mg zinc, 1 mg copper, 75 μ g molybdenum, 250 μ g boron per two tablets) were compared to a clinically proven bone formulation (27 mg natural genistein, 400 IU cholecalciferol, 500 mg elemental calcium (calcium carbonate) per tablet; the Squadrito formulation) in an 8-day steady-state pharmacokinetic (PK) study of healthy postmenopausal women (n = 30) randomized to receive 54 mg of genistein per day. Trough serum samples were obtained before the final dose on the morning of the ninth day followed by sampling at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hrs. Total serum genistein, after β -glucuronidase/sulfatase digestion, was measured by time-resolved fluorometric assay. Maximal time (Tmax), concentration (Cmax), half-life (T1/2), and area under the curve (AUC) were determined for genistein in each formulation. Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL). The OTC supplement's synthetically derived genistein, however, showed altered Tmax (6 hrs), Cmax (0.57 μ M), T1/2 (8.3 ± 1.9 hrs), and AUC (6474 ± 287 ng·hr/mL). Differences in uptake may be due to multiple ingredients in the OTC supplement which interfere with genistein absorption. DOI: 10.1155/2013/273498 PMCID: PMC3591111 PMID: 23484100 [Indexed for MEDLINE]
13. Clin Nutr. 2013 Oct;32(5):686-96. doi: 10.1016/j.clnu.2012.12.010. Epub 2012 Dec 28. Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors. Dawczynski C(1), Massey KA, Ness C, Kiehntopf M, Stepanow S, Platzer M, Grün M, Nicolaou A, Jahreis G. Author information: (1)Department of Nutritional Physiology, Institute of Nutrition, Friedrich Schiller University of Jena, Dornburger Str. 24, D-07743 Jena, Germany. BACKGROUND & AIMS: The study examined the value of n-3 LC-PUFA-enriched yogurt as means of improving cardiovascular health. DESIGN: Fifty three mildly hypertriacylglycerolemic subjects (TAG ≥ 1.7 mmol/L) participated in a randomized, placebo-controlled, double-blind, parallel designed study. The subjects consumed 1) control yoghurt; 2) yoghurt enriched with 0.8 g n-3 LC-PUFA/d; or 3) yoghurt enriched with 3 g n-3 LC-PUFA/d for a period of 10 wks. Blood samples were taken at the beginning and the end of the study period. RESULTS: Following daily intake of 3 g n-3 LC-PUFA for 10 weeks, n-3 LC-PUFA levels increased significantly in plasma and red blood cells (RBC) with concomitant increase in the EPA-derived mediators (PGE₃, 12-, 15-, 18-HEPE) in plasma whilst cardiovascular risk factors such as HDL, TAG, AA/EPA ratio, and n-3 index were improved (P < 0.05); the decrease of TAG and increase in HDL were associated with the CD36 genotype. CONCLUSION: The observed increase of n-3 LC-PUFA in RBC and plasma lipids due to intake of n-3 LC-PUFA enriched yoghurt resulted in a reduction of cardiovascular risk factors and inflammatory mediators showing that daily consumption of n-3 PUFA enriched yoghurt can be an effective way of supplementing the daily diet and improving cardiovascular health. Crown Copyright © 2013. Published by Elsevier Ltd. All rights reserved. DOI: 10.1016/j.clnu.2012.12.010 PMID: 23332800 [Indexed for MEDLINE]
14. Int J Med Sci. 2011 Mar 2;8(3):180-91. doi: 10.7150/ijms.8.180. A comparative effectiveness study of bone density changes in women over 40 following three bone health plans containing variations of the same novel plant-sourced calcium. Kaats GR(1), Preuss HG, Croft HA, Keith SC, Keith PL. Author information: (1)Integrative Health Technologies, Inc, 4940 Broadway, San Antonio, Texas 78209, USA. grk@ihtglobal.com Erratum in Int J Med Sci. 2013;10(9):1135. BACKGROUND: The US Surgeon General's Report on Bone Health suggests America's bone-health is in jeopardy and issued a "call to action" to develop bone-health plans incorporating components of (1) improved nutrition, (2) increased health literacy, and (3) increased physical activity. OBJECTIVE: To conduct a Comparative Effectiveness Research (CER) study comparing changes in bone mineral density in healthy women over-40 with above-average compliance when following one of three bone health Plans incorporating the SG's three components. METHODS: Using an open-label sequential design, 414 females over 40 years of age were tested, 176 of whom agreed to participate and follow one of three different bone-health programs. One Plan contained a bone-health supplement with 1,000 IUs of vitamin D(3 )and 750 mg of a plant-sourced form of calcium for one year. The other two Plans contained the same plant form of calcium, but with differing amounts of vitamin D(3) and other added bone health ingredients along with components designed to increase physical activity and health literacy. Each group completed the same baseline and ending DXA bone density scans, 43-chemistry blood test panels, and 84-item Quality of Life Inventory (QOL). Changes for all subjects were annualized as percent change in BMD from baseline. Using self-reports of adherence, subjects were rank-ordered and dichotomized as "compliant" or "partially compliant" based on the median rating. Comparisons were also made between the treatment groups and two theoretical age-adjusted expected groups: a non-intervention group and a group derived from a review of previously published studies on non-plant sources of calcium. RESULTS: There were no significant differences in baseline BMD between those who volunteered versus those who did not and between those who completed per protocol (PP) and those who were lost to attrition. Among subjects completing per protocol, there were no significant differences between the three groups on baseline measurements of BMD, weight, age, body fat and fat-free mass suggesting that the treatment groups were statistically similar at baseline. In all three treatment groups subjects with above average compliance had significantly greater increases in BMD as compared to the two expected-change reference groups. The group following the most nutritionally comprehensive Plan outperformed the other two groups. For all three groups, there were no statistically significant differences between baseline and ending blood chemistry tests or the QOL self-reports. CONCLUSIONS: The increases in BMD found in all three treatment groups in this CER stand in marked contrast to previous studies reporting that interventions with calcium and vitamin D(3) reduce age-related losses of BMD, but do not increase BMD. Increased compliance resulted in increased BMD levels. No adverse effects were found in the blood chemistry tests, self-reported quality of life and daily tracking reports. The Plans tested suggest a significant improvement over the traditional calcium and vitamin D(3) standard of care. DOI: 10.7150/ijms.8.180 PMCID: PMC3053489 PMID: 21448303 [Indexed for MEDLINE] Conflict of interest statement: Conflict of Interest: The authors have declared that no conflict of interest exists.
15. Res Vet Sci. 2011 Feb;90(1):78-83. doi: 10.1016/j.rvsc.2010.04.016. Epub 2010 May 20. Effect of dietary boron on physiological responses in growing steers inoculated with bovine herpesvirus type-1. Fry RS(1), Brown TT Jr, Lloyd KE, Hansen SL, Legleiter LR, Robarge WP, Spears JW. Author information: (1)Department of Animal Science, North Carolina State University, Box 7621, Raleigh, NC 27695-7621, USA. Thirty-six Angus and Angus×Simmental steers were fed one of three dietary treatments; (1) control (no supplemental B), (2) 5 mg supplemental B/kg, and (3) 15 mg supplemental B/kg for 47 days to determine the effects of dietary boron (B) on disease resistance following an inoculation with bovine herpesvirus type-1 (BHV-1). On day 34 of the study steers were inoculated intranasally with BHV-1. Rectal temperatures began to elevate at day 2, and plasma tumor necrosis factor-α concentrations increased (P<0.05) by day 2 following BHV-1 inoculation. Plasma acute phase proteins were increased (P<0.01) while plasma interferon-γ was decreased (P<0.05) by day 4 post-inoculation. Supplementation of B increased (P<0.001) plasma B concentrations in a dose-responsive manner. However, dietary B did not affect the duration and severity of clinical signs of BHV-1 and had minimal effects on plasma acute phase proteins and cytokines. Copyright © 2010 Elsevier Ltd. All rights reserved. DOI: 10.1016/j.rvsc.2010.04.016 PMID: 20493506 [Indexed for MEDLINE]
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.